About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
All
2024
2023
2022
2021
2020
2019
15
Dec
2020
19:18 E.S.T.
Cellectis Announces Withdrawal of Follow-On Offering
Read more
14
Dec
2020
15:48 E.S.T.
Cellectis Announces Launch of Follow-On Offering
Read more
05
Dec
2020
17:00 E.S.T.
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
Read more
17
Nov
2020
18:58 E.S.T.
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
Read more
16
Nov
2020
16:30 E.S.T.
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer
Read more
05
Nov
2020
16:30 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
Read more
04
Nov
2020
00:00 E.S.T.
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL
Read more
21
Oct
2020
16:30 E.S.T.
Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST
Read more
16
Oct
2020
08:15 E.S.T.
Calyxt Announces $15 Million Registered Direct Offering
Read more
02
Sep
2020
16:30 E.S.T.
Cellectis to Participate in Upcoming Investor Conferences
Read more
1
2
3
Next